AiCuris raises $75M for anti-infectives pipeline

Germany's AiCuris raised close to $75 million in its second venture round, one of the biggest series the country's life sciences industry has seen in recent years. The developer has a pipeline of anti-infectives for herpes simplex virus, HIV, hepatitis B, hepatitis C, and multi-resistant bacteria. And the developer says it is actively seeking out-licensing deals for several of its programs. The company was spun out of Bayer four years ago. AiCuris release | Report

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.